Compile Data Set for Download or QSAR
maximum 50k data
Found 240 Enz. Inhib. hit(s) with Target = 'Tyrosine-protein kinase JAK1 [574-1154]'
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(N-(2-Cyanoethyl)-2-(1-((1r,4r)-4-(cyanomethyl)cycl...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387823(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387821(N-(2-Cyanoethyl)-2-(1-((1r,4r)-4-(cyanomethyl)cycl...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493065(2-((1r,4r)-4-(2-(2-Oxo-2-(4-(trifluoromethyl)piper...)
Affinity DataIC50: <0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493066(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493067(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493068(2-((1r,4r)-4-(2-(1H-1,2,4-Triazol-3-yl)imidazo[4,5...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387823(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493070(2-((1r,4r)-4-(2-(Oxazol-4-yl)imidazo[4,5-d]pyrrolo...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493071(2-((1r,4r)-4-(2-(2-(4-Hydroxypiperidin-1-yl)-2-oxo...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493072(2-Cyano-N-((1-((1r,4r)-4-(cyanomethyl)cyclohexyl)-...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493073(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493074(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493075(2-((1r,4r)-4-(2-(2H-1,2,3-Triazol-4-yl)imidazo[4,5...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493076((E)-N-((1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493078(2-((1r,4r)-4-(2-(2-(3-Hydroxyazetidin-1-yl)-2-oxoe...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493079(N-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-2-(1-((1r,4r...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493080(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493081(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387824(N-(2-Cyano-2-methylpropyl)-2-(1-((1r,4r)-4-(cyanom...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493083(N-(4-Cyanobicyclo[2.2.1]heptan-1-yl)-2-(1-((1r,4r)...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493084(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493085(2-((1r,4r)-4-(2-((1H-Pyrazol-5-yl)methyl)imidazo[4...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50527405(CHEMBL4456630 | US10981911, Example 26)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493087(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493088(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493089(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM505110(US11066406, Ex. 4)
Affinity DataIC50:  0.100nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM505112(US11066406, Ex. 6)
Affinity DataIC50:  0.100nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50: <0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM420028(US10487083, Example B)
Affinity DataIC50: <0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50434787(CHEMBL2386635 | US10487083, Example C | US10703751...)
Affinity DataIC50: <0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387819(2-((1r,4r)-4-(2-(1H-Imidazol-4-yl)imidazo[4,5-d]py...)
Affinity DataIC50:  0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387820(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387824(N-(2-Cyano-2-methylpropyl)-2-(1-((1r,4r)-4-(cyanom...)
Affinity DataIC50:  0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387826(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387819(2-((1r,4r)-4-(2-(1H-Imidazol-4-yl)imidazo[4,5-d]py...)
Affinity DataIC50:  0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387820(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493090(N-((1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihy...)
Affinity DataIC50:  0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493091(2-((1r,4r)-4-(2-(4-Chloro-1H-pyrazol-3-yl)imidazo[...)
Affinity DataIC50:  0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493092(N-((3R,5R)-Adamantan-1-yl)-2-(1-((1r,4r)-4-(cyanom...)
Affinity DataIC50:  0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50527407(CHEMBL4582390 | US10981911, Example 33)
Affinity DataIC50:  0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387825(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493095(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493096(N-((1H-imidazol-2-yl)methyl)-2-(1-((1r,4r)-4-(cyan...)
Affinity DataIC50:  0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493097(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387826(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493099(N-(4-Cyanobenzyl)-2-(1-((1r,4r)-4-(cyanomethyl)cyc...)
Affinity DataIC50:  0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493100(1-((1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihy...)
Affinity DataIC50: <0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493101(2-((1r,4r)-4-(2-(Thiazol-4-ylmethyl)imidazo[4,5-d]...)
Affinity DataIC50: <0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 240 total ) | Next | Last >>
Jump to: